Print
Email
Print Edition Stories
MHT's Julie Donnelly: Boston lines up tech events for fall calendar
Regenerative medicine firms make business of creating skin
Waltham biotech ImmunoGen Inc., which announced today a deal with Novartis worth potentially $250 million, also reported positive clinical data in relation to trastuzumb-DM1, its treatment of breast cancer.
The treatment indicated a 47.8 percent response rate in patients taking T-DM1, compared to a 41.4 percent response rate in patients treated with Herceptin and chemotherapy. T-DM1 also had half the number of serious side effects as the standard Herceptin and chemotherapy treatment, according to ImmunoGen officials.
The news, which was released on Friday, prompted a 6 percent jump in ImmunoGen’s stock price on Friday to $7.10 per share.
Read more about the clinical data results.
ImmunoGen’s news this morning noted that the company had agreed to work with Novartis on targeted anticancer therapeutics developed using ImmunoGen’s Targeted Antibody Payload (TAP) technology, in a deal potentially worth nearly $250 million – and potentially much more.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
